Compare SLNG & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ASMB |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 553.6M |
| IPO Year | N/A | 2010 |
| Metric | SLNG | ASMB |
|---|---|---|
| Price | $5.15 | $32.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $43.40 |
| AVG Volume (30 Days) | 5.4K | ★ 113.5K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $72,270,000.00 | $37,191,000.00 |
| Revenue This Year | $7.02 | $42.01 |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $93.33 | ★ N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $3.29 | $7.75 |
| 52 Week High | $8.28 | $39.71 |
| Indicator | SLNG | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 40.56 |
| Support Level | $4.92 | $35.05 |
| Resistance Level | $5.17 | $36.92 |
| Average True Range (ATR) | 0.14 | 1.93 |
| MACD | 0.01 | -0.57 |
| Stochastic Oscillator | 64.06 | 5.27 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.